Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Lehmann, Sylvain ^a,b   Relano Gines, Aroa ^b   Resina, Sarah ^c   Brillaud, Elsa ^c   Casanova, Danielle ^b   Vincent, Charles ^c   Hamela, Claire ^b   Poupeau, Sophie ^c   Laffont, Mathieu ^c   Gabelle, Audrey ^a   Delaby, Constance ^a   Belondrade, Maxime ^b   Arnaud, Jacques Damien ^d   Alvarez, Maria Teresa ^d   Maurel, Jean Claude ^c   Maurel, Patrick ^c   Crozet, Carole ^a,b  

^a INSERM   (France)

^b INSTITUTE OF HUMAN GENETICS   (France)

^c Medesis Pharma SA   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CXCL9 CHEMOKINE; EOTAXIN; FAS LIGAND; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 9; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PRION PROTEIN; SMALL INTERFERING RNA; SOMATOMEDIN B; THROMBOPOIETIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN LEVEL; CELL COUNT; CELL SURVIVAL; CELL VACUOLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; INCUBATION TIME; MALE; MICROEMULSION; MOUSE; NONHUMAN; PRION DISEASE; PROTEIN EXPRESSION; SURVIVAL TIME;

ANIMALS; ASTROCYTES; BRAIN; CELL COUNT; CYTOKINES; DOWN-REGULATION; FEMALE; GENE TRANSFER TECHNIQUES; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; PRION DISEASES; PRPC PROTEINS; PRPSC PROTEINS; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TIME FACTORS; VACUOLES;

EID: 84895802528     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088797     Document Type: Article

References (22)

1. Sikorska B, Liberski PP (2012) Human prion diseases: from kuru to variant creutzfeldt-jakob disease. Subcell Biochem 65: 457-496.
2. Parchi P, Saverioni D (2012) Molecular pathology, classification, and diagnosis of sporadic human prion disease variants. Folia Neuropathol 50: 20-45.
3. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136-144.
4. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, et al. (1993) Mice devoid of PrP are resistant to scrapie. Cell 73: 1339-1347. (Pubitemid 23201147)
5. Sailer A, Bueler H, Fischer M, Aguzzi A, Weissmann C (1994) No propagation of prions in mice devoid of PrP. Cell 77: 967-968. (Pubitemid 24208856)
6. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, et al. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871-874. (Pubitemid 37339628)
7. Chang K, Elledge SJ, Hannon GJ (2006) Lessons from Nature: microRNA-based shRNA libraries. Nat Methods 3: 707-714. (Pubitemid 44275738)
8. Hannon GJ (2002) RNA interference. Nature 418: 244-251.
9. Mallucci G, Collinge J (2005) Rational targeting for prion therapeutics. Nat Rev Neurosci 6: 23-34. (Pubitemid 40052136)
10. Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, et al. (2007) Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53: 325-335. (Pubitemid 46161264)
11. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, et al. (2008) Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A 105: 10238-10243.
12. White MD, Mallucci GR (2009) RNAi for the treatment of prion disease: a window for intervention in neurodegeneration? CNS Neurol Disord Drug Targets 8: 342-352.
13. White MD, Mallucci GR (2009) Therapy for prion diseases: Insights from the use of RNA interference. Prion 3: 121-128.
14. Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, et al. (2012) NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis 48: 282-289.
15. Parini P, Johansson L, Broijersen A, Angelin B, Rudling M (2006) Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 36: 98-104.
16. Wroblewska M (2011) The origin and metabolism of a nascent pre-beta high density lipoprotein involved in cellular cholesterol efflux. Acta Biochim Pol 58: 275-285.
17. Zannis VI, Chroni A, Krieger M (2006) Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl) 84: 276-294.
18. Brown P (2009) An historical perspective on efforts to treat transmissible spongiform encephalopathy. CNS Neurol Disord Drug Targets 8: 316-322.
19. Toupet K, Compan V, Crozet C, Mourton-Gilles C, Mestre-Frances N, et al. (2008) Effective gene therapy in a mouse model of prion diseases. PLoS ONE 3: e2773.
20. Relano-Gines A, Gabelle A, Lehmann S, Milhavet O, Crozet C (2009) Gene and cell therapy for prion diseases. Infect Disord Drug Targets 9: 58-68.
21. Relano-Gines A, Lehmann S, Bencsik A, Herva ME, Torres JM, et al. (2011) Stem cell therapy extends incubation and survival time in prion-infected mice in a time window-dependant manner. J Infect Dis 2011: 1038-1045.
22. Pulford B, Reim N, Bell A, Veatch J, Forster G, et al. (2010) Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS ONE 5: e11085.